PIQ Financials: Results, Ratios & Statements | Proteomics International Laboratories

PIQ

Proteomics International Laboratories

Pharmaceuticals, Biotechnology & Life Sciences

Proteomics International Laboratories Ltd (ASX:PIQ) is a medical technology company specializing in predictive diagnostics and bio-analytical services. They focus on proteomics, the industrial-scale study of protein structure and function, to develop novel diagnostic tests like PromarkerD, PromarkerEndo, and PromarkerEso, aiming to bring these to global markets.

Short position

short percentage0.40%

reported shorts653.3K

shares on issue165.373M

Proteomics International Laboratories (ASX:PIQ) has 0.40% of its shares on issue reported as short positions as of 5 Oct 2026, or about 653,303 shares. Over the past 30 days that figure has fallen 0.25 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.71% in August 2026. PIQ is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue: $3.4M (source: ASX (Markit))vs $960.4K (FY25); ASX (Markit), as at 29 Sep 2026
NPAT: −$8.6M (source: ASX (Markit))vs −$8.1M (FY25); ASX (Markit), as at 29 Sep 2026
EPS (diluted): −$0.052 (source: Derived: trailing 12 months at year end)vs −$0.060 (FY25); Derived: trailing 12 months at year end, as at 29 Sep 2026

Rev YoY: +250.9%FY
EPS YoY: n/aTTM

ASX (Markit)
Derived: trailing 12 months at year end

Summary of Appendix 4E and Annual Report, 31 Aug 2026

Proteomics International Laboratories reported a net loss after tax of $8.56 million for FY2026, widening 5.5% from the prior year, while total revenue and other income rose 3.0% to $3.61 million. No dividends were declared. The company completed a strategic review, suspended its direct-to-consumer model, and executed a national distribution agreement with Healius, positioning for commercial execution in FY2027.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026

Gross margin: n/a
Operating margin: n/a
Net margin: −254.0%
FCF margin: n/a
ROE: n/a
ROA: n/a
FCF conversion: n/a
Net debt (excl. leases): n/a
Net debt / EBITDA: n/a
Current ratio: n/a
Interest cover: n/a
Cash dividends paid / net profit: n/a
Market cap: n/a (no share count we can vouch for)
P/E: n/a
P/B: n/a (no share count we can vouch for)

Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 29 Sep 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

PIQ income, newest period first, figures in AUD
Line item	FY26	FY25	FY24	FY23
Revenue	$3.4M (source: ASX (Markit))	$960.4K	$892.1K	$730.3K
Gross profit	n/a	$960.4K	$892.1K	$730.3K
Operating income	n/a	−$10.6M	−$9.1M	−$8.8M
EBITDA	n/a	−$10.0M	−$8.4M	−$8.3M
EBIT	n/a	−$10.6M	−$9.1M	−$8.8M
Pretax income	n/a	−$8.2M	−$6.5M	−$6.2M
Tax	n/a	$0	$0	$0
NPAT	−$8.6M (source: ASX (Markit))	−$8.1M	−$6.4M	−$6.2M
Net interest income	n/a	$155.2K	$259.1K	$136.5K
EPS basic	−$0.052 (source: Derived: trailing 12 months at year end)	−$0.060	−$0.051	−$0.053
EPS diluted	−$0.052 (source: Derived: trailing 12 months at year end)	−$0.060	−$0.051	−$0.053
Shares	n/a	163.5M	130.9M	121.0M

ASX (Markit)
Derived: trailing 12 months at year end

Financial reports

The company's own filings, newest first

Showing 10 of 29 reports